View Post

Clinical trial demonstrates focused ultrasound can deliver antibody therapy to breast cancer metastases in the brain

In Clinical Studies News by Barbara Jacoby

By: Focused Ultrasound Foundation From: medicalxpress.com In a first-in-world clinical trial, researchers at Sunnybrook Health Sciences Centre in Toronto, Canada, have demonstrated that magnetic resonance (MR)-guided focused ultrasound can be used to safely deliver antibody therapy to breast cancer that has metastasized to the brain. In this Phase I clinical trial for Her2-positive breast cancer patients, the Sunnybrook team captured …

View Post

Next Oncology Expands Phase I Program with Virginia Cancer Specialists Partnership

In Clinical Studies News by Barbara Jacoby

Internationally known cancer researcher, Dr. Anthony Tolcher, CEO and founder of NEXT Oncology, has entered into a joint venture with Virginia Cancer Specialists (VCS). Dr. Alex Spira of VCS sought to expand the clinic’s Phase I and developmental therapeutics cancer research program and bring the latest in new agents and anticancer treatments to its Research Institute. NEXT Oncology has relationships …

View Post

Radionuclide therapy a promising option to treat HER2 breast cancer

In Clinical Studies News by Barbara Jacoby

From: europeanpharmaceuticalreview.com The radionuclide treatment combines radioactive iodine therapy with single-domain antibodies to target the HER2 antigen. A Phase I trial has found that radionuclide treatment may offer new therapeutic options for human epidermal growth factor receptor type 2 (HER2)-positive breast cancer. The treatment combines radioactive iodine therapy with single-domain antibodies that target the HER2 antigen to destroy cancer cells. …

View Post

JCRI Discovers the Mechanism using Canady Helios™ Cold Plasma to Induce Cell Death in Breast Cancer

In Clinical Studies News by Barbara Jacoby

From: businesswire.com The Jerome Canady Research Institute for Advanced Biological and Technological Sciences (JCRI-ABTS), in collaboration with US Medical Innovations, LLC (USMI), announced today that they have discovered the mechanism using Canady Helios™ Cold Plasma (CHCP) to induce cell death in breast cancer. Recently accepted for publication in the International Journal of Molecular Sciences, the article “Canady Helios Cold Plasma …

View Post

SBRT Safe for Cancer Patients With Multiple Metastases

In Clinical Studies News by Barbara Jacoby

By: Mike Bassett From: medpagetoday.com Late adverse events in phase I trial indicate need for extended follow-up Stereotactic body radiotherapy (SBRT) proved safe for treating cancer patients with multiple metastases, according to a phase I trial. In the NRG-BR001 trial, standard doses of SBRT were safe in 35 patients with oligometastatic breast, prostate, and non-small cell lung cancer (NSCLC) with …

View Post

Oncoceutics Begins Clinical Trial with Next-Generation Imipridone ONC206 at the NIH

In Clinical Studies News by Barbara Jacoby

Oncoceutics, Inc. announced today that the first patient has been treated in a first-in-human clinical trial of the company’s next-generation imipridone ONC206 at the National Institutes of Health (“NIH”). The Phase I trial, for adults with recurrent primary central nervous system (CNS) neoplasms, is led by Mark Gilbert, MD, Chief of the Neuro-Oncology Branch, Center for Cancer Research (CCR), National …

View Post

Killing ‘Sleeper Cells’ May Prevent Relapse in ER+ Breast Cancer Therapy

In Clinical Studies News by Barbara Jacoby

By: Alana Hippensteele, Editor From: pharmacytimes.com The anti-cancer medicine venetoclax may improve the current therapy for estrogen receptor-positive (ER+) breast cancer, according to preclinical studies.1 Led by Walter and Eliza Hall Institute researchers, the new study used breast cancer cells taken from patients and demonstrated that venetoclax was effectively able to kill sleeping, or ‘senescent,’ cancer cells.1 The results from …

View Post

Janssen Pharmaceutical Bispecific Antibody Granted Breakthrough Designation for Lung Cancer Treatment

In Clinical Studies News by Barbara Jacoby

By: Staff Reporter From: precisiononcologynews.com Janssen Pharmaceutical Companies, a unit of Johnson & Johnson, said on Tuesday that its investigational drug JNJ-61186372 (JNJ-6372) has been granted breakthrough therapy designation by the US Food and Drug Administration. The drug is being evaluated in non-small cell lung cancer patients with EGFR exon 20 insertion mutations whose disease has progressed on or after …

View Post

Study Says Combination of MEK, BET Inhibitors May be Effective in Portion of Breast Cancer Patients

In Clinical Studies News by Barbara Jacoby

By: Staff Reporter By: precisiononcologynews.com A new study published in Science Translational Medicine this week found that MET inhibitors in combination with BET inhibitors could be potent against high MYCN-expressing triple negative breast cancer. The authors of the study hope that their findings will accelerate development of BET inhibitors for TNBC, where there is an unmet need. TNBC accounts for …

View Post

Moderna ships first batch of COVID-19 vaccine for Phase I trial; study page posted online

In Clinical Studies News by Barbara Jacoby

By: Alaric DeArment From: medcitynews.com The company said it had shipped the first batch of the vaccine, mRNA-1273, for the NIH-run clinical trial. The study has an estimated start date of March 6, according to ClinicalTrials.gov, while The Wall Street Journal reported it would start in April. A biotech company that is one of several developing vaccines and drugs for …